A Pilot Study of the Safety and Efficacy of SEP-226330 in Subjects with Restless Legs Syndrome.

Trial Profile

A Pilot Study of the Safety and Efficacy of SEP-226330 in Subjects with Restless Legs Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2011

At a glance

  • Drugs SEP 226330 (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top